Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro
Preparation and evaluation of ziprasidone–phospholipid complex from sustained‐release pellet formulation with enhanced bioavailability and no food effect
Tags: atypical antipsychotic (AAP), bipolar disorder, Geodon®, Risperidone analogue, schizophrenia
BASi Method Number SAP.1678
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
